Alzamend Neuro Income Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Selling, General & Admin	5.14	3.08	3.48	7.42	7.12
Research & Development	3.63	1.41	6.46	7.45	5.2
Total Operating Expenses	8.77	4.5	9.94	14.87	12.32
Operating Income	-8.77	-4.5	-9.94	-14.87	-12.32
Interest Income	0	-	-	-	-
Interest Expense	-0.01	-0.02	-0.01	-0.01	-0.05
Other Non-Operating Income (Expense)	-	-	-	-	-0
Total Non-Operating Income (Expense)	-0.01	-0.02	-0.01	-0.01	-0.05
Pretax Income	-8.77	-4.51	-9.95	-14.88	-12.37
Net Income	-8.77	-4.51	-9.95	-14.88	-12.36
Net Income Attributable to Preferred Dividends	-	0.59	-	-	-
Net Income to Common	-8.77	-5.11	-9.95	-14.88	-12.36
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	3	0	0	0	0
Shares Outstanding (Diluted)	3	0	0	0	0
Shares Change	640.27%	507.76%	2.68%	9.46%	22.64%
EPS (Basic)	-2.63	-11.32	-132.33	-206.01	-189.00
EPS (Diluted)	-2.63	-11.32	-132.33	-206.01	-189.00
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Free Cash Flow	-8.07	-6.87	-8.42	-8.92	-6.72
Free Cash Flow Growth	-	-	-	-	-
Free Cash Flow Per Share	-2.42	-15.24	-113.48	-123.53	-101.83
EBITDA	-8.66	-4.45	-9.89	-14.85	-12.32
EBIT	-8.77	-4.5	-9.94	-14.87	-12.32

SEC Filings: 10-K · 10-Q